Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y3E5
UPID:
PTH2_HUMAN
Alternative names:
Bcl-2 inhibitor of transcription 1
Alternative UPACC:
Q9Y3E5; B3KUY4; Q9NTE5
Background:
Peptidyl-tRNA hydrolase 2, mitochondrial, also known as Bcl-2 inhibitor of transcription 1, plays a crucial role in protein synthesis by hydrolyzing peptidyl-tRNAs that detach from the ribosome. Additionally, it promotes caspase-independent apoptosis, influencing transcriptional regulators AES and TLE1.
Therapeutic significance:
Linked to Neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 1, understanding the role of Peptidyl-tRNA hydrolase 2 could open doors to potential therapeutic strategies.